Jean‐Luc Delongeas

A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development

Sally Robinson, Jean‐Luc Delongeas, Elizabeth Donald et al. · Regulatory Toxicology and Pharmacology · 2007 · 104 citations

Drug Safety, Regulatory Requirement, Medicine +10

A global pharmaceutical company initiative: An evidence-based approach to define the upper limit of body weight loss in short term toxicity studies

Kathryn Chapman, Fiona Sewell, Linda Allais et al. · Regulatory Toxicology and Pharmacology · 2013 · 70 citations · Full text

Assessment of Labrasol®/Labrafil®/Transcutol® (4/4/2, v/v/v) as a non-clinical vehicle for poorly water-soluble compounds after 4-week oral toxicity study in Wistar rats

Jean‐Luc Delongeas, G. Vermeil de Conchard, A. Beamonte et al. · Regulatory Toxicology and Pharmacology · 2010 · 29 citations

Pharmacological Study, Pharmacology, Water-soluble Compounds +10

Genetic Toxicity Assessment: Employing the Best Science for Human Safety Evaluation Part II: Performances of the In Vitro Micronucleus Test Compared to the Mouse Lymphoma Assay and the In Vitro Chromosome Aberration Assay

Elisabeth Lorge, Carine Lambert, Véronique Gervais et al. · Toxicological Sciences · 2006 · 25 citations · Full text

Influence of Testicular Secretions on Differentiation in the Rat Epididymis: Ultrastructural Studies after Castration, Efferent Duct Ligation and Cryptorchidism

Jean‐Luc Delongeas, J. L. Gelly, Bruno Leheup et al. · Pathobiology · 1987 · 24 citations

Clear Cells, Reproductive Biology, Cellular Physiology +17